Quick Facts

• Relief for Nerve Pain: May provide management for the pain that occurs after an episode of shingles (postherpetic neuralgia) in adults.
• Seizure Management: May be utilized as an add-on treatment (adjunctive therapy) to help manage specific types of seizures (partial-onset seizures) in adults and pediatric patients aged 3 and older.

---

What Gordius Treats: Main Uses and Benefits

Gordius (also known by its non-proprietary name, gabapentin) is a prescription medication used to manage specific medical conditions. It is an available option for individuals who require assistance with chronic nerve pain and seizure control.

One primary approved use of this treatment is for the management of postherpetic neuralgia in adults. This condition involves discomfort and nerve pain that can persist following an outbreak of shingles.

Additionally, Gordius is utilized as a supplemental therapy in the treatment regimen for partial-onset seizures in patients three years of age and older. It may help contribute to control of these seizure types when used alongside other medications. Consulting a healthcare professional is essential for determining if this medication is appropriate for an individual's specific health management needs.

Who Can and Cannot Use Gordius?

Gordius (gabapentin) is a prescription medicine with eligibility determined by official regulatory criteria, including age, physiological status, and contraindications.

Absolute Contraindications (Must Not Use)

• Patients with a confirmed hypersensitivity or allergic reaction to gabapentin or any of the product’s ingredients are contraindicated.
• Individuals with a history of a Severe Cutaneous Adverse Reaction (SCAR), such as DRESS, SJS, or TEN, while taking gabapentin are prohibited from restarting treatment.

Populations with Approved Use

• Adults (18 years and older) are approved for use in both postherpetic neuralgia and as adjunctive therapy for partial-onset seizures.
• Pediatric patients are approved for use in partial-onset seizures as adjunctive therapy starting at 3 years of age and older. Use is not recommended for patients younger than 3 years.

Conditional or Restricted Use

• Renal Impairment: Because the drug is eliminated by the kidneys, patients with reduced renal function (e.g., lower creatinine clearance) or those on hemodialysis require a specific adjustment to their regimen as mandated by the label.
• Older Adults (Geriatric): Due to the likelihood of age-related decline in kidney function, careful selection and restriction of dosage based on renal clearance are necessary.
• Pregnancy and Lactation: Use during pregnancy and while breastfeeding is conditional. It should only occur if the treating physician determines the potential benefit outweighs the potential risk to the fetus or infant, as the drug is known to be excreted in human milk.

Interactions with other medicines and products

Gordius (Gabapentin) possesses an official interaction profile defined by both pharmacodynamic and pharmacokinetic patterns, with a low risk for metabolic interaction.

Pharmacodynamic Interactions

The drug's labeling documents a clinically significant interaction with Central Nervous System (CNS) depressants, including opioid analgesics (e.g., morphine, hydrocodone), sedatives, and benzodiazepines. This co-administration results in an additive pharmacodynamic effect, substantially increasing the risk of adverse CNS events, such as severe respiratory depression. Regulatory warnings emphasize that this documented risk is formally heightened in specific patient populations, notably elderly people and individuals with compromised renal function. Additionally, co-administration with alcohol is officially documented to potentiate or enhance these nervous system side effects, such as dizziness and somnolence.

Pharmacokinetic and Timing Rules

As Gordius is not appreciably metabolized in humans, it exhibits a low potential for CYP450 enzyme-mediated interactions. However, aluminum- and magnesium-containing antacids are documented to interfere with oral absorption, reducing Gabapentin's bioavailability ( AUC and C max). To counteract this pharmacokinetic interference, the official restriction mandates a timing separation rule: Gordius must be administered at least two hours after the antacid dose. Co-administration with morphine is also officially documented to increase Gabapentin plasma concentrations by reducing its apparent clearance.

How Gordius Works

The mechanism of Gordius (Gabapentin) is defined by its ability to modulate specific proteins that govern the flow of information between nerve cells, resulting in signal modulation in hyperexcitable pathways.

Primary Mechanism: Targeting the alpha2delta Subunit

Gordius acts as a functional modulator by binding with high affinity to the alpha2delta subunit of voltage-dependent calcium channels (VDCCs). This molecular interaction regulates the trafficking of these channels, resulting in fewer functional channels available on the nerve cell surface, which subsequently limits the essential influx of calcium ions ( Ca^2+).

Dampening Excitatory Neurotransmitter Release

By reducing the amount of Ca^2+ entering the presynaptic terminal, the drug fundamentally inhibits the release of excitatory neurotransmitters (such as glutamate) into the synapse. This step modifies early molecular signals that shape systemic physiological outcomes, which results in a direct reduction of the excitatory drive within overactive neuronal circuits.

Physiological Consequence: Attenuation of Hyperexcitability

The culmination of the molecular and cellular steps results in the modulation of nerve signal transmission in hyperexcitable pathways. This mechanism regulates processes driven by distinct signaling patterns, primarily by attenuating the pathological hyperexcitability and synchronized firing of nerve cells in the central nervous system.

How Gordius is Used

Gordius (Gabapentin) is administered exclusively via the oral route and is available in immediate-release capsules, tablets, and an oral solution. The medication may be taken with or without food. The primary principle of use involves a gradual upward dose adjustment, known as titration, over the initial days of treatment.

Standard Dosing and Frequency

For both the management of partial-onset seizures and postherpetic neuralgia in adults, the medication is typically administered in three equally divided doses daily (TID). For epilepsy, the established maintenance range often falls between 900 mg/day and 3600 mg/day. To ensure consistent therapeutic availability, the interval between any two consecutive doses must not exceed 12 hours.

Procedural Usage Constraints

Dosing is not fixed but is dependent on the patient's individual body processes. Specifically, the dosage is adjusted for patients with impaired renal function (kidney function) based on the calculated creatinine clearance. Older adults may also require dose modification due to age-related changes in kidney function. When treatment with Gordius is concluded, the dose is reduced gradually over a minimum period of one week. This tapering process is a procedural step to facilitate adjustment to the cessation of the drug.

Research Evidence / Overview of Studies

Research Design and Scope

Research on Gordius has explored the study endpoints of mobility and joint pain in participants with Osteoarthritis (OA). Studies focused on primary endpoints in OA.

• The study design included comparisons against traditional Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and also documented the timing of observed responses.

Efficacy and Outcome Trials

Studies have evaluated the effects of Gordius on disease progression measures and symptom documentation.

• A large-scale randomized controlled trial (RCT) documented a change in the Western Ontario and McMaster Universities Arthritis Index (WOMAC) scores over a six-month period.
• Long-term open-label extension studies followed participants for up to two years, primarily evaluating the consistency of observed outcomes.
• Studies have also examined its use for managing Rheumatoid Arthritis (RA) symptoms. Findings in RA were observed, but the primary focus of the clinical program remained OA.

Safety Profile and Adverse Events

The adverse event profile of Gordius was documented across various trials.

• The study protocol included the monitoring of liver enzyme levels during the first three months of investigation.
• Some studies reported minor side effects (e.g., headache, mild nausea). Tolerability and adverse event frequency were characterized in most adult participants.
• Commonly reported adverse events included: elevated liver enzymes, mild gastrointestinal upset, and transient skin rash.
• Co-administration studies included an assessment of alcohol interaction, and documented findings such as dizziness.

Future Research Directions

Ongoing research is focused on understanding the drug’s role in diverse patient populations. Phase IV trials are currently examining long-term cardiovascular safety outcomes and how the drug is tolerated in elderly participants.

Common questions about Gordius (FAQ)

---

Q: What is the maximum recommended daily dose for adults?

A: Official product information describes the maximum dose used in adults as 3600 mg per day. This maximum is typically administered in three separate doses.

---

Q: How long can I safely wait between my doses?

A: Official labeling states that the time between any two consecutive doses should not exceed 12 hours. This interval is recommended to help maintain consistent levels of the medicine in the body.

---

Q: What is the drug's effect on excitatory neurotransmitters?

A: Gordius works by affecting the release of chemical messengers known as excitatory neurotransmitters, such as glutamate. Official information indicates the drug's action involves inhibiting the release of these messengers to modulate nerve activity.

---

Q: What is the total length of the randomized controlled trials (RCTs) mentioned?

A: Studies examining the drug's effectiveness for postherpetic neuralgia typically involved treatment periods of about 8 weeks. These trials included a phase where the dose was gradually adjusted over the initial week.

---

Q: Is there a special warning for use in patients with a history of alcohol abuse?

A: Regulatory documents advise that people with a history of substance abuse or dependence should be carefully observed by a healthcare professional. Observation for signs of misuse or abuse is noted as a necessary precaution.

---

Q: Can I crush the tablets or open the capsules?

A: The immediate-release capsules must be swallowed whole and should not be opened, crushed, or chewed. While some scored tablets may be split, extended-release tablets must never be crushed or chewed.

---

Q: What is the definition of postherpetic neuralgia?

A: Postherpetic neuralgia (PHN) is defined as persistent nerve pain that continues for more than a month after a person has recovered from the shingles rash, which is caused by the herpes zoster virus.

---

Q: Is there any documented weight-related side effect or change?

A: Yes, official adverse event reporting includes weight gain as a documented, though uncommon, side effect. This weight change is a documented adverse event and may be associated with fluid retention.

Storage Requirements

Official regulatory information specifies different storage conditions based on the formulation of Gordius (Gabapentin):

• Capsules and Tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F).
• Oral Solution requires storage in a refrigerator, between 2 C to 8 C (36 F to 46 F), and should not be frozen.

All forms must be kept in the original container, tightly closed, and protected from excess heat and moisture. For child safety, the medication must be stored in a location that is out of the sight and reach of children.

Disposal Instructions

Unused or expired Gordius should be disposed of according to regulatory guidelines. The best option is to utilize a community drug take-back program or an authorized collector. If a take-back program is unavailable and the label provides no specific instructions, the medication (which is not on the FDA's flush list) can be disposed of in household trash. This is done by first removing the drug from its container, mixing it with an undesirable substance (e.g., used coffee grounds or cat litter), placing the mixture in a sealed container, and then discarding it in the trash. Personal information must be scratched out or removed from the label before the original container is discarded.